Article Sidebar

pdf
Date Published: 27/01/2025
Abstract Views: 303
Views pdf: 127
DOI: https://doi.org/10.51298/vmj.v546i1.12502
Issue
Vol. 546 No. 1 (2025)
Section
Các bài báo
How to Cite
Lê, H., Nguyễn, N. M., Nguyễn, T. N. Q., Nguyễn, Đông D., & Đỗ, T. H. (2025). THE ROLE OF IMMUNOHISTOCHEMICAL IN CLASSIFICATION OF LUNG CANCER. Vietnam Medical Journal, 546(1). https://doi.org/10.51298/vmj.v546i1.12502

THE ROLE OF IMMUNOHISTOCHEMICAL IN CLASSIFICATION OF LUNG CANCER

Hoàn Lê, Ngọc Minh Nguyễn, Thị Như Quỳnh Nguyễn, Đông Dương Nguyễn, Thu Huyền Đỗ

Main Article Content

Abstract

Objective: To evaluate the role of immunohistochemical staining in histopathological classification of lung cancer at Hanoi Medical University Hospital. Subjects and Methods: A retrospective descriptive study on 142 patients diagnosed with primary lung cancer at Hanoi Medical University Hospital from January 2022 to December 2023. Results: Adenocarcinoma accounts for 85.9%, squamous carcinoma accounts for 8.5%, small cell carcinoma accounts for 4.2% and other types account for 1.4%. Immunohistochemical staining was performed in 40/142 cases, of which: adenocarcinoma was positive for TTF1 in 22/22 (100%) and Napsin A in 19/22 (86.4%) cases; squamous cell carcinoma showed p40 positivity in 10/10 (100%) cases; neuroendocrine markers were positive in all small cell carcinomas. Conclusion: Immunohistochemistry helps determine the histopathological type of lung cancer in cases where Hematoxylin-Eosin staining cannot be determined.

Article Details

Keywords

Lung cancer, immunohistochemical staining

References

1. Sung H. Ferlay J., Siegel RL., et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J Clin. 2021 May;71(3):209-249. DOI: 10.3322/caac.21660.
2. WHO Classification of Tumours Editorial Board, Thoracic Tumours, 5th ed. International Agency for Research on Cancer. 2021.
3. Trần Khánh Chi, Lê Tuấn Minh, Lê Hoàn và cộng sự. Nồng độ Cyfra 21-1 và NSE trong máu ở bệnh nhân ung thư phổi tại Bệnh viện Bạch Mai 2013-2014. Tạp chí nghiên cứu Y học. 2015;Số chuyên đề tháng 11: 142-147
4. Phạm Nguyên Cường. Nghiên cứu đặc điểm mô bệnh học và hóa mô miễn dịch của ung thư phổi tại Khoa Giải phẫu bệnh- Bệnh viện Trung ương Huế. Tạp chí Y học lâm sàng. 2020, 66: 23-28.
5. Zhang Y, Vaccarella S, Morgan E, et al. Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol. 2023 Nov;24(11):1206-1218. DOI: 10.1016/S1470-2045(23)00444-8.
6. Powell CA, Brambilla E, et al. Molecular testing for treatment selection in lung cancer WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. International Agency for Research on Cancer (IARC). 2015 4th ed:22-37
7. Sainz, Fukuoka, et al. Napsin-A: a new marker for lung adenocarcinoma is complementary and more sensitive than TTF-1 (thyroid transcription factor-1): evaluation of 967 cases by tissue microarray. Mod Pathol. 2008: 213 – 249
8. Alekhya M, Rukmangadha N, Lakshmi AY, et al. Role of Immunohistochemistry in The Subtyping of Non Small Cell Lung Carcinoma on True Cut Lung Biopsies. Ann Pathol Lab Med. 2018; 56A:447- 455. DOI: https://doi.org/ 10.21276/apalm.1839.
9. Ye J, Findeis-Hosey JJ, Yang Q, et al. Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung. Appl Immunohistochem Mol Morphol. 2011 Jul;19(4):313-7. DOI: 10.1097/PAI.0b013e318205b059.
10. Camilo R, Capelozzi VL, Siqueira SAC, et al. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Hum Pathol. 2006 May;37(5):542-6. DOI: 10.1016/j.humpath.2005.12.019.